E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Mild Cognitive Impairment |
Declino Cognitivo Lieve |
|
E.1.1.1 | Medical condition in easily understood language |
Cognitive Impairment |
Declino cognitivo |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10009843 |
E.1.2 | Term | Cognitive deterioration |
E.1.2 | System Organ Class | 100000004852 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Identification of regional patterns of Neuraceq cortical ritention |
Identificazione di pattern regionali di ritenzione corticale del Neuraceq |
|
E.2.2 | Secondary objectives of the trial |
Evaluation of the pattern of regional Neuraceq cortical retention as predictors of conversion to AD.
Evaluation of regional pattern of Neuraceq retention and semi-quantitative data analysis as predictors of conversion to AD |
Valutazione dei pattern regionali di ritenzione corticale del Neuraceq come predittori di conversione ad AD.
Valutazione dei pattern regionali di ritenzione del Neuraceq e dei dati di analisi semi-quantitativa come predittori di conversione ad AD |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Diagnosis of MCI according to the criteria of Petersen
History of cognitive decline and cognitive impairment at the neuropsychological
evaluation
> 60 years of age
Absence of criteria for the diagnosis of vascular dementia
score> 24 on the Mini-Mental State Examination
No history of addiction to alcohol or drugs
Absence of psychiatric illness
Willingness to give informed consent
|
Diagnosi di MCI secondo i criteria di Petersen
Storia di declino cognitivo e deterioramento cognitivo alla valutazione neurospicologica
>60 anni di età
Assenza di criteri per la diagnosi di demenza vascolare
Punteggio >24 al Mini-Mental State Examination
Assenza di storia di dipendenza da alcool o da droghe
Assenza di malattie psichiatriche
Disponibilità a dare il consenso informato
|
|
E.4 | Principal exclusion criteria |
Diagnosis of dementia according to the ICD-10 criteria
• Score ≤ 23 at the Mini-Mental State Examination
• Diagnosis of Vascular dementia
• Presence of psychiatric illness
• Presence of diseases or medications that may alter the function or brain structures
• A history of bleeding in the brain
• Previous ischemic stroke
• Presence of brain tumor
• Presence of hydrocephalus
•Epatic and renal abnormalities |
• Diagnosi di Demenza secondo i criteri ICD-10
•Punteggio ≤ 23 al Mini-Mental State Examination
•Diagnosi di Demenza vascolare
•Presenza di malattie psichiatriche
•Presenza di malattie o assunzione di farmaci che possono alterare la funzione o la strutture cerebrali
•Pregresse emorragie cerebrali
•Pregresso ictus ischemico
•Presenza di tumore cerebrale
•Presenza di idrocefalia
•Alterazioni epatiche e renali |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Evaluation of the frequency of specific patterns of Neuraceq retention in patients who convert to AD and in patients who do not convert to AD. |
Valutazione della frequenza di specifici pattern di ritenzione del Neuraceq nei pazienti che convertono ad AD e nei pazienti che non convertono ad AD. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Evaluation of specific patterns of Neuraceq retention and SUVR as predictors of conversion from MCI to AD, through statistical regression analysis. |
Valutazione di specifici pattern di ritenzione del Neuraceq e degli SUVR come predittori di conversione da MCI ad AD, tramite analisi statistica di regressione. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 0 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 0 |